Atlas Trials

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Clinical trial NCT06561360 · RECRUITING

Trial details

NCT number
NCT06561360
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hairy Cell Leukemia
Start date
2024-09-09
Primary completion
2027-09-09
Enrollment
86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.